Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,430 | 1 | 65.0% |
| Food and Beverage | $664.00 | 8 | 17.8% |
| Unspecified | $641.80 | 4 | 17.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,716 | 3 | $0 (2023) |
| Eli Lilly and Company | $641.80 | 4 | $0 (2020) |
| AbbVie Inc. | $198.14 | 4 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $179.86 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,716 | 3 | Janssen Scientific Affairs, LLC ($2,716) |
| 2020 | $614.44 | 4 | Eli Lilly and Company ($589.00) |
| 2019 | $97.26 | 2 | AbbVie, Inc. ($97.26) |
| 2018 | $165.78 | 2 | Novartis Pharmaceuticals Corporation ($90.34) |
| 2017 | $142.32 | 2 | Novartis Pharmaceuticals Corporation ($89.52) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2023 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $2,430.00 | General |
| Category: Immunology | ||||||
| 11/13/2023 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Food and Beverage | In-kind items and services | $143.00 | General |
| Category: Immunology | ||||||
| 11/13/2023 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Food and Beverage | In-kind items and services | $143.00 | General |
| Category: Immunology | ||||||
| 12/16/2020 | AbbVie Inc. | RINVOQ (Drug) | Food and Beverage | In-kind items and services | $25.44 | General |
| Category: IMMUNOLOGY | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $175.00 | Research |
| Study: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | ||||||
| 07/09/2020 | Eli Lilly and Company | — | — | In-kind items and services | $268.60 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | ||||||
| 07/09/2020 | Eli Lilly and Company | — | — | In-kind items and services | $145.40 | Research |
| Study: A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | ||||||
| 10/02/2019 | AbbVie, Inc. | Rinvoq (Biological) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Immunology | ||||||
| 03/04/2019 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $79.77 | General |
| 04/23/2018 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $75.44 | General |
| Category: Immunology | ||||||
| 02/28/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $90.34 | General |
| 08/28/2017 | Eli Lilly and Company | — | — | In-kind items and services | $52.80 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | ||||||
| 05/08/2017 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $89.52 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $268.60 | 1 |
| A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | Eli Lilly and Company | $175.00 | 1 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $145.40 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $52.80 | 1 |
About Dr. Jane Box, MD
Dr. Jane Box, MD is a Rheumatology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467436220.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jane Box, MD has received a total of $3,736 in payments from pharmaceutical and medical device companies, with $2,716 received in 2023. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,430).
Practice Information
- Specialty Rheumatology
- Location Charlotte, NC
- Active Since 12/05/2005
- Last Updated 01/21/2014
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1467436220
Products in Payments
- STELARA (Biological) $2,716
- COSENTYX (Biological) $89.52
- Humira (Biological) $75.44
- RINVOQ (Drug) $25.44
- Rinvoq (Biological) $17.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Charlotte
Gordon Lam, Md, MD
Rheumatology — Payments: $3.1M
Dr. Andrew Laster, Md, MD
Rheumatology — Payments: $751,361
Dr. Heather Gladue, Do, DO
Rheumatology — Payments: $207,205
Firas Kassab, M.d, M.D
Rheumatology — Payments: $71,224
Dr. Alireza Nami, M.d, M.D
Rheumatology — Payments: $56,705
John Brendese, M.d., Facr, M.D., FACR
Rheumatology — Payments: $21,513